Optiscan Imaging Limited: Difference between revisions
>Paris Created page with "Optiscan Imaging Limited develops and commercializes confocal endomicroscopes for clinical and pre-clinical applications in Australia, the United States, China, and Germany. It offers FIVE2 (ViewnVivo) system, a miniaturized confocal endomicroscopes designed for translational and pre-clinical research. The company also engages in the development of InVivage device for use in cancer screening and surgery. Optiscan Imaging Limited was founded in 1994 and is headquartered i..." |
No edit summary |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
== Summary == | |||
Optiscan Imaging Limited develops and commercializes confocal endomicroscopes for clinical and pre-clinical applications in Australia, the United States, China, and Germany. It offers FIVE2 (ViewnVivo) system, a miniaturized confocal endomicroscopes designed for translational and pre-clinical research. The company also engages in the development of InVivage device for use in cancer screening and surgery. Optiscan Imaging Limited was founded in 1994 and is headquartered in Mulgrave, Australia. | Optiscan Imaging Limited develops and commercializes confocal endomicroscopes for clinical and pre-clinical applications in Australia, the United States, China, and Germany. It offers FIVE2 (ViewnVivo) system, a miniaturized confocal endomicroscopes designed for translational and pre-clinical research. The company also engages in the development of InVivage device for use in cancer screening and surgery. Optiscan Imaging Limited was founded in 1994 and is headquartered in Mulgrave, Australia. | ||
__INDEX__ | |||
Latest revision as of 11:31, 20 August 2022
Summary edit edit source
Optiscan Imaging Limited develops and commercializes confocal endomicroscopes for clinical and pre-clinical applications in Australia, the United States, China, and Germany. It offers FIVE2 (ViewnVivo) system, a miniaturized confocal endomicroscopes designed for translational and pre-clinical research. The company also engages in the development of InVivage device for use in cancer screening and surgery. Optiscan Imaging Limited was founded in 1994 and is headquartered in Mulgrave, Australia.